Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Manhattan Scientifics Signs LOI to Acquire Rights to Early Cancer Detection System Developed by Dr. Edward R. Flynn

Abstract:
Manhattan Scientifics (OTCBB: MHTX) announced today that it has entered into a non-binding letter of intent (LOI) with Edward R. Flynn, Ph.D. and his company, Senior Scientific, LLC, to acquire all the manufacturing and marketing rights, together with all commercial rights associated with Dr. Flynn's patents and IP in the emerging field of nanomedicine. Dr. Flynn's work is focused on the biomagnetic detection of cancer and other diseases through magnetic field sensors with enhanced accuracy.

Manhattan Scientifics Signs LOI to Acquire Rights to Early Cancer Detection System Developed by Dr. Edward R. Flynn

Albuquerque, NM | Posted on October 20th, 2009

The details of the planned acquisition were not disclosed. A definitive agreement is expected to be concluded within 60 days.

Manhattan's CEO Manny Tsoupanarias stated, "Our intended acquisition of Dr. Flynn's novel early cancer detection system is a perfect fit with our company's focus on commercializing nanotechnologies in the field of advanced medicine."

Marvin Maslow, chairman emeritus of Manhattan Scientifics, said, "It is not merely our goal, but our obligation to bring Dr. Flynn's extraordinary work in the field of early cancer detection and potential treatment to the world medical community. Just as we have demonstrated in the past, we intend to identify one or more appropriate Fortune 500 industrial partners in the pharmaceutical and medical device industries to bring product to the market."

Edward R. Flynn, Ph.D. is a LANL Laboratory Fellow where he was originally a nuclear physicist for 25 years and published 185 scientific papers. He then changed to medical physics where he started the Biophysics group at the Los Alamos National Laboratory and initiated the Brain Research Program publishing 65 scientific papers. Thereafter he pioneered important cancer work as President and founder of Senior Scientific, LLC, a privately-held company.

Dr. Flynn stated, "I used my knowledge of physics to apply sophisticated magnetic field sensors for very small fields, SQUIDs (Superconducting Quantum Interference Devices) capable of measuring extremely small magnetic fields for the detection of various types of cancer, by using magnetic nanoparticles targeted specifically toward the cancer cells. The SQUID sensor I developed has the ability to detect the small magnetic fields from nanoparticles that have attached to the cancer cells. With this biomagnetic imaging technique, it is possible to identify and image small clusters of cancer cells in a rather novel method, substantially increasing the sensitivity for finding cancer at an earlier stage than is currently available, and without the use of ionizing radiation or large magnetic fields. This biomagnetic sensor method is applicable to breast, ovarian, leukemia, prostate, skin melanoma, and other cancers." Dr. Flynn continued, "This research has been funded by Small Business Innovative Research Grants from the National Institutes of Health. Senior Scientific collaborates with the University of New Mexico Health Sciences Center. Research has reached the stage where instrumentation development is viable to attain significantly earlier detection of a variety of cancers. Moreover, I am confident that by partnering with Manhattan Scientifics now, our team will achieve the ultimate goals of the program."

####

About Manhattan Scientifics
Manhattan Scientifics, Inc., www.mhtx.com, is located in New Mexico, New York, and Montreal. It is developing and plans to acquire technologies in a variety of environmentally friendly nanotechnology, energy and other people-friendly industries.

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

For more information, please click here

Contacts:
Executive Contacts:
Manhattan Scientifics, Inc.
Manny Tsoupanarias
Chief Executive Officer
918-919-0370

or
Technical Contact:
Senior Scientific, LLC
Edward R. Flynn, Ph.D.
President & CEO
505-243-1058 Lab Direct

or
Investor Relations Contact:
Premier Media Service Inc.
Kelly Black
or
Heather Mund, 480-649-8224


or
Manhattan Scientifics, Inc.
Marvin Maslow
Director of Investor Relations
917-923-3300

or
Institutional Investor Relations:
Hawk Associates
Frank Hawkins
305-451-1888

www.hawkassociates.com/profile/mhtx.cfm

Copyright © Business Wire 2009

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Virginia Tech physicists propose path to faster, more flexible robots: Virginia Tech physicists revealed a microscopic phenomenon that could greatly improve the performance of soft devices, such as agile flexible robots or microscopic capsules for drug delivery May 17th, 2024

Gene therapy relieves back pain, repairs damaged disc in mice: Study suggests nanocarriers loaded with DNA could replace opioids May 17th, 2024

Shedding light on perovskite hydrides using a new deposition technique: Researchers develop a methodology to grow single-crystal perovskite hydrides, enabling accurate hydride conductivity measurements May 17th, 2024

Oscillating paramagnetic Meissner effect and Berezinskii-Kosterlitz-Thouless transition in cuprate superconductor May 17th, 2024

Nanomedicine

Virginia Tech physicists propose path to faster, more flexible robots: Virginia Tech physicists revealed a microscopic phenomenon that could greatly improve the performance of soft devices, such as agile flexible robots or microscopic capsules for drug delivery May 17th, 2024

Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024

Advances in priming B cell immunity against HIV pave the way to future HIV vaccines, shows quartet of new studies May 17th, 2024

New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024

Sensors

Innovative sensing platform unlocks ultrahigh sensitivity in conventional sensors: Lan Yang and her team have developed new plug-and-play hardware to dramatically enhance the sensitivity of optical sensors April 5th, 2024

$900,000 awarded to optimize graphene energy harvesting devices: The WoodNext Foundation's commitment to U of A physicist Paul Thibado will be used to develop sensor systems compatible with six different power sources January 12th, 2024

A color-based sensor to emulate skin's sensitivity: In a step toward more autonomous soft robots and wearable technologies, EPFL researchers have created a device that uses color to simultaneously sense multiple mechanical and temperature stimuli December 8th, 2023

New tools will help study quantum chemistry aboard the International Space Station: Rochester Professor Nicholas Bigelow helped develop experiments conducted at NASA’s Cold Atom Lab to probe the fundamental nature of the world around us November 17th, 2023

Announcements

Virginia Tech physicists propose path to faster, more flexible robots: Virginia Tech physicists revealed a microscopic phenomenon that could greatly improve the performance of soft devices, such as agile flexible robots or microscopic capsules for drug delivery May 17th, 2024

Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024

Finding quantum order in chaos May 17th, 2024

Oscillating paramagnetic Meissner effect and Berezinskii-Kosterlitz-Thouless transition in cuprate superconductor May 17th, 2024

Patents/IP/Tech Transfer/Licensing

Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023

Study finds nanomedicine targeting lymph nodes key to triple negative breast cancer treatment: In mice, nanomedicine can remodel the immune microenvironment in lymph node and tumor tissue for long-term remission and lung tumor elimination in this form of metastasized breast cance May 13th, 2022

Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project